Prescribing Information Important Risk Information
Thank you for your interest in the LILETTA + LILETTA Patient Commitment Program®*. This program has been discontinued effective November 1, 2018 for new enrollees. Per the Program Terms and Conditions, participation is still valid through October 31, 2022 for eligible patients who enrolled in the program on or before October 31, 2018. If you are an eligible patient who had their first LILETTA inserted on or before October 31, 2018, and applied to participate in the program and submitted your EOB within 60 days of their insertion date, please call 855-706-4508 for questions or information about your enrollment.
*Depending on insurance coverage, eligible patients who received their first LILETTA on or before October 31, 2018 may have their out-of-pocket cost for a second LILETTA reduced to $0, up to a maximum savings limit of $700. Offer applies to product only, and does not apply to costs associated with medical examination or product administration. Check with pharmacist or healthcare provider for copay discount. Patient out-of-pocket expense may vary. Offer not valid for patients enrolled in Medicare, Medicaid, or other federal or state healthcare programs. Please see LILETTA + LILETTA PATIENT COMMITMENT PROGRAMSM Terms and Conditions here.
Indication

LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg is a hormone-releasing system placed in your uterus to prevent pregnancy for as long as you want for up to 5 years.

Important Risk Information About LILETTA

LILETTA does not protect against HIV or STDs.

Available by prescription only.

Please see full Prescribing Information.

Reference: 1. LILETTA (levonorgestrel-releasing intrauterine system) 52 mg [Prescribing Information]. Irvine, CA: Allergan and Medicines360; 2018.